<?php
/**
 * MinMaxMuscle Forum - Pending thread creation: Ribupatide
 * Generated: 2026-11-03 (daily discovery run)
 * Instructions: Upload to blog.minmaxmuscle.com and run via SSH, OR apply
 *               directly via Asgaros Forum admin panel if REST endpoint is available.
 *
 * Usage:
 *   ssh user@blog.minmaxmuscle.com "php /tmp/20261103_ribupatide.php"
 *
 * Alternatively, if Asgaros REST endpoint available:
 *   POST /wp-json/asgaros-forum/v1/topics
 *   Authorization: Basic <base64(WP_USER:WP_APP_PASSWORD)>
 */

// WordPress bootstrap - adjust path if needed
define('ABSPATH', dirname(__FILE__) . '/');
require_once('/var/www/html/wp-load.php');

$topic_title   = 'New Research Thread: Ribupatide (HRS9531) — Oral & Injectable GLP-1/GIP Dual Agonist (Kailera/Hengrui)';
$topic_content = <<<EOT
<p><strong>Compound overview:</strong> Ribupatide (HRS9531) is a GLP-1/GIP dual agonist by Hengrui + Kailera being developed in both injectable (Phase 3 globally) and oral pill forms (Phase 2 positive → Phase 3 planned). The oral form would be the first oral GLP-1/GIP dual agonist to reach Phase 3.</p>

<p><strong>Key data points:</strong></p>
<ul>
  <li>Oral Phase 2 China (ADA 2026, NCT06841445, N=166): up to 12.1% weight loss at 26 weeks, 38.6% achieved ≥15% reduction; weight loss not yet plateaued at 26 weeks</li>
  <li>Injectable Phase 3 China: 23.6% mean weight loss at 36 weeks — among the highest Phase 3 obesity numbers reported</li>
  <li>Safety: consistent with GLP-1 class; well tolerated</li>
  <li>Global oral Phase 2 planned 2026; global Phase 3 targeted H1 2027</li>
</ul>

<p><strong>Why this is interesting:</strong> Current GLP-1/GIP therapy (tirzepatide/Zepbound) requires weekly injections. If oral ribupatide delivers ~12–15%+ weight loss in a pill (no injection needed), it could massively expand access to dual-incretin therapy. The 26-week trajectory for oral ribupatide is not plateauing yet, hinting at 15–20% possible with longer duration.</p>

<p><strong>Discuss:</strong> How significant is the "oral vs. injectable" difference for patient adoption? Is 12% at 26 weeks (oral) competitive with injectable GLP-1s? How does HRS9531 compare to what we know about oral semaglutide (Rybelsus)?</p>

<p><em>Research compounds discussed for educational purposes. Not FDA-approved for human use where applicable. Consult a healthcare provider before use.</em></p>
EOT;

// Asgaros Forum direct insert (adjust forum_id as needed — use forum ID for "Peptide Research" board)
global $wpdb;
$forum_id = 1; // Update to actual Peptide Research forum ID

$result = $wpdb->insert(
    $wpdb->prefix . 'asgarosforum_threads',
    [
        'title'      => $topic_title,
        'content'    => $topic_content,
        'forum_id'   => $forum_id,
        'author_id'  => 1,
        'date'       => current_time('mysql'),
        'approved'   => 1,
        'pinned'     => 0,
        'closed'     => 0,
    ]
);

if ($result) {
    $thread_id = $wpdb->insert_id;
    echo "Forum thread created: ID {$thread_id}\n";
    echo "Title: {$topic_title}\n";
    // Update D1 forum_topic_url: https://blog.minmaxmuscle.com/forum/topic/{$thread_id}/
} else {
    echo "Error creating thread: " . $wpdb->last_error . "\n";
}
